|
|
| Research article summary (published 20 Oct 2009): |
Strict blood-pressure control and progression of renal failure in children.
Full Abstract
BACKGROUND: Although inhibition of the renin-angiotensin system delays the progression of renal failure in adults with chronic kidney disease, the blood-pressure target for optimal renal protection is controversial. We assessed the long-term renoprotective effect of intensified blood-pressure control among children who were receiving a fixed high dose of an angiotensin-converting-enzyme (ACE) inhibitor. METHODS: After a 6-month run-in period, 385 children, 3 to 18 years of age, with chronic kidney disease (glomerular filtration rate of 15 to 80 ml per minute per 1.73 m(2) of body-surface area) received ramipril at a dose of 6 mg per square meter of body-surface area per day. Patients were randomly assigned to intensified blood-pressure control (with a target 24-hour mean arterial pressure below the 50th percentile) or conventional blood-pressure control (mean arterial pressure in the 50th to 95th percentile), achieved by the addition of antihypertensive therapy that does not target the renin-angiotensin system; patients were followed for 5 years. The primary end point was the time to a decline of 50% in the glomerular filtration rate or progression to end-stage renal disease. Secondary end points included changes in blood pressure, glomerular filtration rate, and urinary protein excretion. RESULTS: A total of 29.9% of the patients in the group that received intensified blood-pressure control reached the primary end point, as assessed by means of a Kaplan-Meier analysis, as compared with 41.7% in the group that received conventional blood-pressure control (hazard ratio, 0.65; confidence interval, 0.44 to 0.94; P=0.02). The two groups did not differ significantly with respect to the type or incidence of adverse events or the cumulative rates of withdrawal from the study (28.0% vs. 26.5%). Proteinuria gradually rebounded during ongoing ACE inhibition after an initial 50% decrease, despite persistently good blood-pressure control. Achievement of blood-pressure targets and a decrease in proteinuria were significant independent predictors of delayed progression of renal disease. CONCLUSIONS: Intensified blood-pressure control, with target 24-hour blood-pressure levels in the low range of normal, confers a substantial benefit with respect to renal function among children with chronic kidney disease. Reappearance of proteinuria after initial successful pharmacologic blood-pressure control is common among children who are receiving long-term ACE inhibition. (ClinicalTrials.gov number, NCT00221845.) 2009 Massachusetts Medical Society
Author information
Author/s: ESCAPE Trial Group; Wühl, Elke (E); Trivelli, Antonella (A); Picca, Stefano (S); Litwin, Mieczyslaw (M); Peco-Antic, Amira (A); Zurowska, Aleksandra (A); Testa, Sara (S); Jankauskiene, Augustina (A); Emre, Sevinc (S); Caldas-Afonso, Alberto (A); Anarat, Ali (A); Niaudet, Patrick (P); Mir, Sevgi (S); Bakkaloglu, Aysin (A); Enke, Barbara (B); Montini, Giovanni (G); Wingen, Ann-Margret (AM); Sallay, Peter (P); Jeck, Nikola (N); Berg, Ulla (U); Caliskan, Salim (S); Wygoda, Simone (S); Hohbach-Hohenfellner, Katharina (K); Dusek, Jiri (J); Urasinski, Tomasz (T); Arbeiter, Klaus (K); Neuhaus, Thomas (T); Gellermann, Jutta (J); Drozdz, Dorota (D); Fischbach, Michel (M); Möller, Kristina (K); Wigger, Marianne (M); Peruzzi, Licia (L); Mehls, Otto (O); Schaefer, Franz (F);
Journal and publication information
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal: The New England journal of medicine (N Engl J Med), published in United States. (Language: eng)
Reference: 2009-Oct; vol 361 (issue 17) : pp 1639-50
Dates: Created 2009/10/22; Completed 2009/10/29;
PMID: 19846849, status: MEDLINE (last retrieval date: 10/29/2009, IMS Date: )
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
Comments and Corrections
CommentIn: N Engl J Med. 2009 Oct 22;361(17):1701-3. (PMID: 19846857)
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
Related articles
These are the highest related articles currently in the database:
- Efficacy and safety of benazepril for advanced chronic renal insufficiency.
10 Jan 2006 - Tolerability of 10 mg of ramipril in normotensive Indian patients.
29 Jun 2002 - Renoprotective therapy: titration against urinary protein excretion.
29 Jul 1999 - Renoprotective therapy: is it blood pressure or albuminuria that matters?
27 Feb 2005 - Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.
27 Feb 2005 - ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.
29 Nov 2001 - [ACE inhibitors in high risk heart patients. Primary analysis of the HOPE study]
27 Feb 2002 - [ACE inhibitor therapy until end of life?]
27 Oct 2004 - Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*.
27 Feb 2006 - [Ramipril in the treatment of moderate to moderately severe hypertension. A multicenter open study]
30 May 1998
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a large map of 100+ related articles.